Brought to you by 
BMS acquires diabetes player Amylin for $6.8bn
19 Dec 2013
Executive Summary
After months of speculation that that it was up for sale and being pursued by multiple Big Pharma companies, publicly traded diabetes drug developer Amylin Pharmaceuticals Inc. announced it will be acquired by Bristol-Myers Squibb Co. for $6.8bn, consisting of $5.1bn in equity (based on 164mm outstanding Amylin shares) plus $1.7bn in combined Amylin net debt and a contractual payment that Amylin owes to Eli Lilly & Co. The $31-per-share cash price represents a 99% premium to the ten-day average leading up to late March 2012 reports that BMS had made a takeover bid.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS acquires diabetes player Amylin for $6.8bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice